EAM
Eventide Asset Management Portfolio holdings
AUM
$5.71B
This Quarter Return
+9.88%
1 Year Return
+51.18%
3 Year Return
+209.28%
5 Year Return
+283.63%
10 Year Return
+1,480.39%
AUM
$5.45B
AUM Growth
+$5.45B
(+7.5%)
Cap. Flow
+$45.9M
Cap. Flow
% of AUM
0.84%
Top 10 Holdings %
Top 10 Hldgs %
26.99%
Holding
160
New
17
Increased
65
Reduced
42
Closed
14
Top Buys
| 1 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$43.8M |
| 2 |
Doximity
DOCS
|
$42.6M |
| 3 |
Palo Alto Networks
PANW
|
$30.3M |
| 4 |
Lithia Motors
LAD
|
$28.7M |
| 5 |
Sarepta Therapeutics
SRPT
|
$25.8M |
Top Sells
| 1 |
GTM
ZoomInfo Technologies
GTM
|
$79.2M |
| 2 |
DoubleVerify
DV
|
$40.7M |
| 3 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$38.9M |
| 4 |
Immunovant
IMVT
|
$35.7M |
| 5 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$32.7M |
Sector Composition
| 1 | Healthcare | 43.08% |
| 2 | Technology | 24.5% |
| 3 | Industrials | 13.06% |
| 4 | Consumer Discretionary | 7.01% |
| 5 | Utilities | 3.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRNS
76
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $21.9M | 0.4% |
3,173,197
+23,197
| +0.7% | +$160K |
|
|
77
Immunovant
IMVT
$2.88B
| $21.6M | 0.4% |
1,390,000
-2,303,720
| -62% | -$35.7M |
|
78
BILL Holdings
BILL
$4.68B
| $21.5M | 0.39% |
264,398
-912
| -0.3% | -$74K |
|
79
Prothena Corp
PRTA
$447M
| $21.3M | 0.39% |
438,732
| – | – |
|
80
Nasdaq
NDAQ
$53.5B
| $21.2M | 0.39% |
388,601
-82,982
| -18% | -$4.54M |
|
81
Williams Companies
WMB
$70.4B
| $21M | 0.39% |
704,707
-58,232
| -8% | -$1.74M |
|
82
KLA
KLAC
$110B
| $20.4M | 0.37% |
51,159
+597
| +1% | +$238K |
|
83
Novanta
NOVT
$4B
| $20M | 0.37% |
125,954
+54
| +0% | +$8.59K |
|
84
Repligen
RGEN
$6.6B
| $20M | 0.37% |
119,000
| – | – |
|
|
BPMC
85
DELISTED
Blueprint Medicines
BPMC
| $19.7M | 0.36% |
438,500
| – | – |
|
86
Cytokinetics
CYTK
$5.86B
| $19.6M | 0.36% |
556,000
| – | – |
|
87
908 Devices
MASS
$203M
| $19.2M | 0.35% |
2,230,665
| – | – |
|
88
Intuitive Surgical
ISRG
$157B
| $19.2M | 0.35% |
75,029
+29
| +0% | +$7.41K |
|
89
Intellia Therapeutics
NTLA
$1.26B
| $18.4M | 0.34% |
493,222
+174,222
| +55% | +$6.49M |
|
90
FibroGen
FGEN
$48.2M
| $17.9M | 0.33% |
+960,000
| New | +$17.9M |
|
91
Bruker
BRKR
$4.41B
| $17.4M | 0.32% |
220,803
+18,797
| +9% | +$1.48M |
|
92
Equity Lifestyle Properties
ELS
$11.7B
| $16.6M | 0.3% |
246,737
+123,352
| +100% | +$8.28M |
|
93
Veracyte
VCYT
$2.38B
| $16.3M | 0.3% |
732,000
| – | – |
|
94
BioMarin Pharmaceuticals
BMRN
$11.3B
| $16M | 0.29% |
164,299
-65,701
| -29% | -$6.39M |
|
|
BLU
95
DELISTED
BELLUS Health Inc.
BLU
| $15.9M | 0.29% |
+2,210,000
| New | +$15.9M |
|
96
BridgeBio Pharma
BBIO
$9.89B
| $15.6M | 0.29% |
+941,176
| New | +$15.6M |
|
97
Insmed
INSM
$30.2B
| $15.6M | 0.29% |
912,103
+213,690
| +31% | +$3.64M |
|
98
Rocket Pharmaceuticals
RCKT
$358M
| $15.4M | 0.28% |
898,000
+427,346
| +91% | +$7.32M |
|
99
Pentair
PNR
$17.4B
| $15M | 0.28% |
271,505
-78,895
| -23% | -$4.36M |
|
100
Sysco
SYY
$38.8B
| $14.8M | 0.27% |
191,333
+14,233
| +8% | +$1.1M |
|